DiaMedica Therapeutics Inc Cash Flow Conversion Efficiency
DiaMedica Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, DiaMedica Therapeutics Inc (DMAC) has a cash flow conversion efficiency ratio of -0.192x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.08 Million) by net assets ($47.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of DiaMedica Therapeutics Inc (2004–2025)
Cash flow conversion efficiency of DiaMedica Therapeutics Inc from 2004 to 2025. This chart illustrates how DiaMedica Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View DMAC stock price and chart for real-time trading data and today's change.
DiaMedica Therapeutics Inc Cash Flow Conversion Ratio Explained
DiaMedica Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
DiaMedica Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DiaMedica Therapeutics Inc ranked by their cash flow conversion efficiency. Also see DMAC market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Qumei Furniture Group Co Ltd
SHG:603818
|
0.062x |
|
Lifezone Metals Limited
NYSE:LZM
|
-0.117x |
|
Eche Izquierdo
SN:EISA
|
0.071x |
|
Chieftek Precision Co Ltd
TW:1597
|
0.051x |
|
Borussia Dortmund GmbH & Co KGaA
XETRA:BVB
|
0.014x |
|
Anhui Xinbo Aluminum Co Ltd
SHE:003038
|
-0.149x |
|
D-Link Corp
TW:2332
|
-0.022x |
|
Pan Asia Chemical Co
TWO:4707
|
0.017x |
Annual Cash Flow Conversion Efficiency for DiaMedica Therapeutics Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of DiaMedica Therapeutics Inc from 2004 to 2025. Review free cash flow generation of DiaMedica Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $56.11 Million | $-29.06 Million | -0.518x | +4.47% |
| 2024-12-31 | $40.72 Million | $-22.08 Million | -0.542x | -47.81% |
| 2023-12-31 | $51.06 Million | $-18.73 Million | -0.367x | -1.42% |
| 2022-12-31 | $31.83 Million | $-11.51 Million | -0.362x | -29.96% |
| 2021-12-31 | $44.02 Million | $-12.25 Million | -0.278x | +21.18% |
| 2020-12-31 | $26.01 Million | $-9.19 Million | -0.353x | +70.45% |
| 2019-12-31 | $7.62 Million | $-9.10 Million | -1.195x | -257.17% |
| 2018-12-31 | $17.02 Million | $-5.70 Million | -0.335x | +93.15% |
| 2017-12-31 | $799.00K | $-3.90 Million | -4.881x | -101.17% |
| 2016-12-31 | $1.25 Million | $-3.02 Million | -2.426x | -318.40% |
| 2015-12-31 | $-1.23 Million | $-1.37 Million | 1.111x | -54.77% |
| 2014-12-31 | $-1.53 Million | $-3.76 Million | 2.456x | +161.68% |
| 2013-12-31 | $1.38 Million | $-5.50 Million | -3.983x | -64.48% |
| 2012-12-31 | $2.26 Million | $-5.48 Million | -2.421x | -320.16% |
| 2011-12-31 | $5.96 Million | $-3.44 Million | -0.576x | -106.67% |
| 2010-12-31 | $8.52 Million | $-2.38 Million | -0.279x | +86.39% |
| 2009-12-31 | $1.05 Million | $-2.15 Million | -2.049x | -288.44% |
| 2008-12-31 | $2.78 Million | $-1.47 Million | -0.528x | -76.73% |
| 2007-12-31 | $4.06 Million | $-1.21 Million | -0.299x | +75.65% |
| 2006-12-31 | $653.60K | $-801.16K | -1.226x | +25.36% |
| 2005-12-31 | $506.11K | $-831.17K | -1.642x | -1852.50% |
| 2004-12-31 | $-1.06 Million | $-99.35K | 0.094x | -- |
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal… Read more